Basiliximab
Indications
Basiliximab is used for:
Acute graft rejection in renal transplantation
Adult Dose
Intravenous
Prophylaxis of Renal Transplant Rejection
20 mg IV within 2 hr prior to transplant surgery, THEN
20 mg IV 4 days after transplant
Used in regimen containing cyclosporine and corticosteroids
Child Dose
Prophylaxis of Renal Transplant Rejection
>35 kg: Administer as in adults; 20 mg IV within 2 hr prior to transplant surgery, THEN, 20 mg IV 4 days after transplant
<35 kg: 10 mg IV within 2 hr prior to transplant surgery, THEN 10 mg IV 4 days after transplant
Used in regimen containing cyclosporine and corticosteroids
Renal Dose
Administration
IV Preparation
Reconstitute vials with 5 mL SWI
Dilute reconstituted contents in 50 mL NS or D5W
IV Administration
For central or intravenous administration only
Infuse over 20-30 min
Contra Indications
Hypersensitivity to basiliximab and murine proteins.
Precautions
Should be prescribed only by physicians who have experience with immunosuppression in organ transplant recipients and can provide necessary follow-up and appropriate monitoring.
Development of human antimurine antibodies reported for murine products.
The risk of developing lymphoproliferative disorders may increase with immunosuppressive therapy.
Immunosuppressive therapy may increase the risk of opportunistic infection.
Pregnancy-Lactation
Pregnancy Category: B
Lactation: Unknown whether excreted in milk; because of the potential for adverse reactions, a decision should be made to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother
Interactions
Immunosuppressives other than ciclosporin and corticosteroids may increase the potential for over-immunosuppression.
May diminish response to inactivated vaccines.
May enhance the adverse/ toxic effect of live vaccines, avoid concomitant admin.
Contraindicated (1)
upadacitinib
Adverse Effects
Side effects of Basiliximab :
Peripheral oedema, hypertension, atrial fibrillation; fever, headache, insomnia, pain; wound complication, acne; hypokalaemia, hyperglycaemia, hyperuricaemia, hypophosphataemia, hypercholesterolaemia; GI effects; UTI; anaemia; tremor; dyspnoea, infection.
Rarely, hypersensitivity and anaphylactoid-type reactions.
Mechanism of Action
Basiliximab, a chimeric murine/human monoclonal antibody, blocks the ?-chain of the interleukin-2 receptor complex on the surface of activated T-lymphocytes.